Search results for "TYR"

showing 10 items of 2017 documents

Dose-dependent metabolic disposition of hydroxytyrosol and formation of mercapturates in rats

2013

Hydroxytyrosol (HT), one of the major polyphenols present in olive oil, is known to possess a high antioxidant capacity. The aim of the present study was to investigate dose dependent (0, 1, 10 and 100 mg/kg) alterations in the metabolism of HT in rats since it has been reported that metabolites may contribute to biological effects. Special attention was paid to the activation of the semiquinone quinone oxidative cycle and the formation of adducts with potential deleterious effects. Thus, we developed a novel analytical methodology to monitor the in vivo formation of the HT mercapturate, N-acetyl-5-S-cysteinyl-hydroxytyrosol in urine samples. Biomarkers of hepatic and renal toxicity were ev…

MaleMercapturate adductsPharmacologyGlucuronidation PathwayAntioxidantschemistry.chemical_compoundSulfationIn vivoHomovanillyl alcoholAnimalsPharmacologyGlutathione Oxidative damageHydroxytyrosol metabolismDose-Response Relationship DrugGlutathione DisulfidePolyphenolsGlutathioneMetabolismPhenylethyl AlcoholGlutathioneAcetylcysteineRatsBiochemistrychemistryToxicityHydroxytyrosolFemale
researchProduct

Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study.

2006

The effect of aspirin on dopaminergic neuronal damage induced by in vivo infusion of 1-methyl-4-phenylpiridinium iodide (MPP(+)) and 6-hydroxydopamine (6-OHDA) was studied in rats, using microdialysis. Rat striata were perfused with 1 mM MPP(+) or 6-OHDA for 10 min, causing peak levels of dopamine (DA) in the dialytic fluid, after 40 min. After 24 h, 1 mM MPP(+) was perfused again for 10 min and DA levels measured in the dialytic fluid, as an index of neuronal cell integrity. Pretreatment with Aspidol (lysine acetylsalicylate), 180 mg/kg i.p., 1 h before MPP(+) or 6-OHDA perfusion, did not modify DA extracellular output, on day 1, but restored MPP(+)-induced DA release on day 2, indicating …

MaleMicrodialysisTyrosine 3-MonooxygenaseDopamineMicrodialysisNeurotoxinsPharmacologyNeuroprotectionSettore BIO/09 - FisiologiaRats Sprague-Dawleychemistry.chemical_compoundIn vivoHydroxybenzoatesNeurotoxinAnimalsDrug InteractionsMolecular BiologyChromatography High Pressure LiquidNeuronsAnalysis of VarianceAspirinGeneral NeuroscienceMPTPDopaminergicImmunohistochemistryCorpus StriatumRatsNeuroprotective Agentsnervous systemchemistryAnesthesiaNerve DegenerationNeurology (clinical)Aspirin in vivo microdialysisPerfusionOxidopamineDevelopmental Biology
researchProduct

Anticonvulsants do not suppress long-term potentiation (LTP) in the rat hippocampus

1991

Long-term potentiation (LTP) of population spikes in the CA1 area of rat hippocampus was induced by tetanic stimulation of stratum radiatum in slices kept submerged in a perfusion chamber. Addition of the two antiepileptic drugs phenytoin or the diazepine midazolam to the medium did not significantly alter this phenomenon within 22 min after the tetanus. The early enhancement (post-tetanic potentiation, PTP) was reduced only by phenytoin. Therefore an interaction of these drugs with N-methyl-D-aspartate (NMDA) receptors and LTP induction is unlikely.

MaleMidazolammedicine.medical_treatmentPopulationHippocampusIn Vitro TechniquesPharmacologyNeurotransmissionHippocampusLTP inductionmedicineAnimalseducationEvoked Potentialsgamma-Aminobutyric Acideducation.field_of_studyChemistryGeneral NeuroscienceRats Inbred StrainsLong-term potentiationRatsAnticonvulsantnervous systemPhenytoinSynapsesNMDA receptorAnticonvulsantsFemaleTetanic stimulationNeuroscience Letters
researchProduct

Effects of localmelatonin application on post-extraction sockets after third molar surgery: a pilot study

2014

Objectives: The purpose of this study was to assess the anti-inflammatory, analgesic and osteogenic early effects of melatonin on post-extraction sockets ofpatients requiring third molars extraction. Study Design: A randomized, triple-blind clinical trial was made using a split-mouth design. Both lower third molars of 10 patients were extracted and 3 mg of local melatonin or placebo were applied. Concentrations of interleukin-6 and nitrotyrosine were determined on samples of the clot from the socket by independent ELISA tests. Radiographic bone density was evaluated by measuring Hounsfield Units in panoramic and cross sections obtained by digital scanner. Statistycal analysis by Kolmogorov-…

MaleMolarBone densityAdministration TopicalRadiographyDentistryPilot ProjectsOdontologíaPlaceboMelatoninYoung Adultchemistry.chemical_compoundDouble-Blind MethodBone DensityHounsfield scalemedicineHumansTooth SocketGeneral DentistryDental alveolusMelatoninInterleukin-6business.industryResearchNitrotyrosine:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologychemistryTooth ExtractionUNESCO::CIENCIAS MÉDICASFemaleMolar ThirdSurgeryOral Surgerybusinessmedicine.drug
researchProduct

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, second…

2002

Abstract Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response…

MaleMyeloidmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsBiochemistryTyrosine-kinase inhibitorPiperazinesBone MarrowRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary Acute Myeloid LeukemiaHumansReceptors Platelet-Derived Growth FactorEnzyme InhibitorsneoplasmsSalvage TherapyChemotherapyAnemia Refractory with Excess of Blastsbusiness.industryAnemia RefractoryDaunorubicinRemission InductionCytarabineMyeloid leukemiaCell BiologyHematologyExonsMiddle Agedmedicine.diseaseNeoplasm ProteinsLeukemiaLeukemia Myeloid AcuteProto-Oncogene Proteins c-kitmedicine.anatomical_structureImatinib mesylatePyrimidinesDrug Resistance NeoplasmImmunologyBenzamidesCancer researchDisease ProgressionImatinib MesylateNeoplastic Stem CellsBone marrowbusinessBlood
researchProduct

Role of GABAergic antagonism in the neuroprotective effects of bilobalide

2006

Bilobalide, a constituent of Ginkgo biloba, has neuroprotective properties. Its mechanism of action is unknown but it was recently found to block GABA(A) receptors. The goal of this study was to test the potential role of a GABAergic mechanism for the neuroprotective activity of bilobalide. In rat hippocampal slices exposed to NMDA, release of choline indicates breakdown of membrane phospholipids. NMDA-induced choline release was almost completely blocked in the presence of bilobalide (10 microM) and under low-chloride conditions. Bicuculline (100 microM), a competitive antagonist at GABA(A) receptors, reduced NMDA-induced choline release to a small extent (-23%). GABA (100 microM) partiall…

MaleN-MethylaspartateBrain EdemaCyclopentanesIn Vitro TechniquesPharmacologyBicucullineInhibitory postsynaptic potentialHippocampusArticlegamma-Aminobutyric acidCholineGABA AntagonistsRats Sprague-Dawleychemistry.chemical_compoundBilobalideExcitatory Amino Acid AgonistsmedicineAnimalsPicrotoxinDrug InteractionsFuransMolecular Biologygamma-Aminobutyric AcidChemistryGABAA receptorGeneral NeuroscienceBicucullineGABA receptor antagonistBridged Bicyclo Compounds HeterocyclicRatsGinkgolidesNeuroprotective Agentsnervous systemNonlinear DynamicsMechanism of actionArea Under CurveGABAergicNeurology (clinical)medicine.symptomSynaptosomesDevelopmental Biologymedicine.drugBrain Research
researchProduct

NMDA-GABA interactions in an animal model of behaviour: a gating mechanism from motivation toward psychotic-like symptoms

1994

We studied the effects of desipramine, alprazolam, muscimol and dizocilpine (MK-801) (alone or associated with desipramine) in the forced swimming test in rats after long-lasting termination of chronic exposure to vehicle and pentylenetetrazol. Sensitisation with pentylenetetrazol was ineffective in changing immobility time in the forced swimming test compared to vehicle treatment; pentylenetetrazol enhanced the anti-immobility effect of desipramine, abolished the anti-immobility effect of alprazolam and did not affect the anti-immobility effect of muscimol. MK-801 at the dose that did not modify immobility time in vehicle-treated rats and in pentylenetetrazol-treated animals strongly poten…

MaleN-MethylaspartatePoison controlGatingMotor ActivityPharmacologybehavioral disciplines and activitieschemistry.chemical_compoundDesipramineKindling NeurologicmedicineAnimalsPharmacology (medical)Rats WistarPentylenetetrazolSwimminggamma-Aminobutyric AcidBiological PsychiatryPharmacologyMotivationAlprazolamBehavior AnimalMuscimolDesipramineRatsnervous system diseasesDizocilpineDisease Models AnimalPsychiatry and Mental healthPsychotic DisordersNeurologyAlprazolamMuscimolchemistryAnesthesiaPentylenetetrazoleNeurology (clinical)Dizocilpine MaleatePsychologymedicine.drugBehavioural despair testEuropean Neuropsychopharmacology
researchProduct

Intensity of GABA-evoked responses is modified by nitric oxide-active compounds in the subthalamic nucleus of the rat: a microiontophoretic study.

2009

We have previously described modulatory effects of nitric oxide (NO)-active drugs on subthalamic nucleus (STN) neurons. In this study, the effects of microiontophoretically applied NO-active compounds on GABA-evoked responses were investigated in subthalamic neurons extracellularly recorded from anesthetized rats: 45 of 62 cells were excited by S-nitroso-glutathione (SNOG), an NO donor, whereas 28 of 43 neurons were inhibited by N-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor. Nearly all neurons responding to SNOG and/or L-NAME showed significant inhibitory responses to the administration of iontophoretic GABA. In these cells, the changes induced by NO-active drugs in the magnitud…

MaleNOS inhibitormedicine.drug_classBiophysicsAction PotentialsGlutamic AcidPharmacologyNeurotransmissionInhibitory postsynaptic potentialBicucullineNitric OxideSettore BIO/09 - FisiologiaNitric oxideGABA AntagonistsCellular and Molecular Neurosciencechemistry.chemical_compoundSubthalamic NucleusmedicineAnimalsDrug InteractionsNitric Oxide DonorsEnzyme InhibitorsRats Wistargamma-Aminobutyric AcidNeuronssubthalamic nucleus GABA SNOG L-NAMEIontophoresisBicucullineIontophoresisReceptor antagonistElectric StimulationRatsSubthalamic nucleusNG-Nitroarginine Methyl Esternervous systemchemistryS-Nitrosoglutathionemedicine.drugJournal of neuroscience research
researchProduct

The gamma(2)-MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors.

2001

Using the latency for tail-flick after thermal stimulation we have assessed the effects of alpha-, gamma(1)- and gamma(2)-MSH on nociceptive threshold in the mice. Intracisternal injections of gamma(2)-MSH induced a distinct analgesia, while gamma(1)-MSH in the same doses gave only a minor analgesia. Intracisternal alpha-MSH instead gave a short-term hyperalgesia. The effect of gamma(2)-MSH was not blocked by any of the MC(4)/MC(3)receptor antagonist HS014, naloxone or by the prior intracisternal administrations of gamma(1)-MSH. However, the gamma(2)-MSH analgesic response was completely attenuated by treating animals with the GABA(A)antagonist bicuculline. The gamma(2)-MSH analgesic effect…

MaleNarcotic Antagonists(+)-NaloxonePharmacologyGABA Antagonistschemistry.chemical_compoundMiceEndocrinologyDrug Interactionsgamma-Aminobutyric AcidAnalgesicsMice Inbred BALB Cintegumentary systemMuscimolNaloxoneReceptors MelanocortinNociceptorsGeneral MedicineReceptor antagonistNeurologyHyperalgesiamedicine.symptomhormones hormone substitutes and hormone antagonistsmedicine.drugPain ThresholdTailendocrine systemmedicine.medical_specialtyanimal structuresmedicine.drug_classCatalepsyBicucullinePeptides CyclicCellular and Molecular Neurosciencegamma-MSHMelanocortin receptorInternal medicinemedicineAnimalsGABA ModulatorsGABA AgonistsCatalepsyDiazepamEthanolEndocrine and Autonomic SystemsAntagonistCentral Nervous System DepressantsBicucullinemedicine.diseaseEndocrinologyMuscimolchemistryReceptors Corticotropinalpha-MSHNeuropeptides
researchProduct

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia : results from a randomized, placebo-controlled …

2013

Purpose The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the antileukemic activity of standard induction and consolidation therapy with or without the addition of the kinase inhibitor sorafenib in elderly patients with AML. Patients and Methods All patients received standard cytarabine and daunorubicin induction (7+3 regimen) and up to two cycles of intermediate-dose cytarabine consolidation. Two hundred one patients were equally randomly assigned to receive either sorafenib or placebo between the chemotherapy cycles and subsequently for up to 1 year after the beginning of therapy. The primary ob…

MaleNiacinamideSorafenibOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPlacebo-controlled studyMedizinPlaceboDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProtein Kinase InhibitorsAgedAged 80 and overChemotherapybusiness.industryPhenylurea CompoundsConsolidation ChemotherapyMiddle AgedSorafenibSurgeryLeukemia Myeloid AcuteRegimenfms-Like Tyrosine Kinase 3OncologyTolerabilityMutationCytarabineFemalebusinessmedicine.drug
researchProduct